(Q35814374)

10 August 2017

1 reference

title

The role of pharmacogenomics in the prediction of efficacy of anti-TNF therapy in patients with Crohn's disease (English)

1 reference

10 August 2017

0 references

0 references

1 reference

2

Stefan Schreiber

1 reference

10 August 2017

Silvia Mascheretti

1

1 reference

10 August 2017

1 July 2004

1 reference

10 August 2017

1 reference

10 August 2017

5

1 reference

10 August 2017

5

1 reference

10 August 2017

479-486

1 reference

Inheritance and drug response

10 August 2017

1 reference

https://api.crossref.org/works/10.1517%2F14622416.5.5.479

Pharmacogenomics--drug disposition, drug targets, and side effects

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14622416.5.5.479

A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease. Crohn's Disease cA2 Study Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14622416.5.5.479

Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14622416.5.5.479

Strategies for targeting tumour necrosis factor in IBD.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14622416.5.5.479

Efficacy and safety of retreatment with anti-tumor necrosis factor antibody (infliximab) to maintain remission in Crohn's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14622416.5.5.479

Association of NOD2 leucine-rich repeat variants with susceptibility to Crohn's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14622416.5.5.479

A frameshift mutation in NOD2 associated with susceptibility to Crohn's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14622416.5.5.479

Association of NOD2 (CARD 15) genotype with clinical course of Crohn's disease: a cohort study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14622416.5.5.479

The NOD: a signaling module that regulates apoptosis and host defense against pathogens

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14622416.5.5.479

Nod2, a Nod1/Apaf-1 family member that is restricted to monocytes and activates NF-kappaB

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14622416.5.5.479

21 January 2018

Emerging cytokine family

1 reference

https://api.crossref.org/works/10.1517%2F14622416.5.5.479

The TNF receptor superfamily of cellular and viral proteins: activation, costimulation, and death

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14622416.5.5.479

A metalloproteinase disintegrin that releases tumour-necrosis factor-alpha from cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14622416.5.5.479

Cloning of a disintegrin metalloproteinase that processes precursor tumour-necrosis factor-alpha

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14622416.5.5.479

The TNF-TNF receptor system

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14622416.5.5.479

Human leukocyte antigens class II and tumor necrosis factor genetic polymorphisms are independent predictors of non-Hodgkin lymphoma outcome

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14622416.5.5.479

Relation between tumour necrosis factor polymorphism TNFalpha-308 and risk of asthma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14622416.5.5.479

Association of the tumour necrosis factor alpha -308 but not the interleukin 10 -627 promoter polymorphism with genetic susceptibility to primary sclerosing cholangitis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14622416.5.5.479

Tumor necrosis factor alpha promoter polymorphisms influence the phenotypic expression of hereditary hemochromatosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14622416.5.5.479

Association of TNF-alpha-857C with inflammatory bowel disease in the Australian population

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14622416.5.5.479

Crohn's disease is associated with novel polymorphisms in the 5'-flanking region of the tumor necrosis factor gene

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14622416.5.5.479

Infliximab for the treatment of fistulas in patients with Crohn's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14622416.5.5.479

Chimeric anti-TNF-alpha monoclonal antibody cA2 binds recombinant transmembrane TNF-alpha and activates immune effector functions

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14622416.5.5.479

Infliximab but not etanercept induces apoptosis in lamina propria T-lymphocytes from patients with Crohn's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14622416.5.5.479

Infliximab maintenance therapy for fistulizing Crohn's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14622416.5.5.479

Long term safety of infliximab

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14622416.5.5.479

Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14622416.5.5.479

The safety profile of infliximab in patients with Crohn's disease: the Mayo clinic experience in 500 patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14622416.5.5.479

The relationship between infliximab treatment and lymphoma in Crohn's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14622416.5.5.479

Autoimmunity associated with anti-tumor necrosis factor alpha treatment in Crohn's disease: a prospective cohort study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14622416.5.5.479

Etanercept for active Crohn's disease: a randomized, double-blind, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14622416.5.5.479

Predictors of response to infliximab in patients with Crohn's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14622416.5.5.479

Early Australian experience with infliximab, a chimeric antibody against tumour necrosis factor-alpha, in the treatment of Crohn's disease: is its efficacy augmented by steroid-sparing immunosuppressive therapy? The Infliximab User Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14622416.5.5.479

ANCA pattern and LTA haplotype relationship to clinical responses to anti-TNF antibody treatment in Crohn's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14622416.5.5.479

Protective strategies against ischemic injury of the liver

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14622416.5.5.479

Association between polymorphism in IgG Fc receptor IIIa coding gene and biological response to infliximab in Crohn's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14622416.5.5.479

Influence of Immunogenicity on the Long-Term Efficacy of Infliximab in Crohn's Disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14622416.5.5.479

Demographic and clinical parameters influencing the short-term outcome of anti-tumor necrosis factor (infliximab) treatment in Crohn's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14622416.5.5.479

Serological markers for prediction of response to anti-tumor necrosis factor treatment in Crohn's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14622416.5.5.479

NOD2/CARD15 does not influence response to infliximab in Crohn's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14622416.5.5.479

Pharmacogenetic investigation of the TNF/TNF-receptor system in patients with chronic active Crohn's disease treated with infliximab

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14622416.5.5.479

Response to infliximab treatment in Crohn's disease is not associated with mutations in the CARD15 (NOD2) gene: an analysis in 534 patients from two multicenter, prospective GCP-level trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14622416.5.5.479

21 January 2018

Identifiers

DOI

10.1517/14622416.5.5.479

1 reference

10 August 2017

1 reference

PubMed ID

15212584